Losartan Potassium

TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders. This time last year, Scienture Holdings, Inc. (f.k.a. TRxADE Health, Inc.). was focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. The primary operations were conducted through our wholly-owned subsidiary, Integra Pharma Solutions, LLC (“IPS”), which is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. We completed a sale of assets of our subsidiary TRXaDE Inc. to Micro Merchant Systems for $22.5 million in Q1 2024 and entered into a business combination with Scienture, Inc., a private branded and specialty pharmaceutical company, in an all-stock transaction valued at $103 million. This completed our transformation to a company focused on the development of a novel and innovative specialty product pipeline that provides comprehensive access and disease management solutions to patients, caregivers and the healthcare system. Today, we are a fully fitted branded and specialty pharmaceutical company through our wholly-owned Scienture, LLC subsidiary, with two (2) FDA approved commercial products to be launched in the second half of 2025. We received NDA approval for our first in-house product (ArbliTM) from the FDA and completed the strategic acquisition of a previously approved product (REZENOPY®) in March 2025. We have put together an accomplished commercial operations infrastructure and go to market capabilities, for bringing novel and innovative brand products to the market. Our R&D focus continues to be in place with our proprietary product pipeline in development by leveraging the 505b-2 NDA and BLA regulatory pathways, identifying and contracting with key technology partners and service providers for product development, manufacturing and clinical operations. We are also in the process of divesting our legacy subsidiaries related to healthcare IT and pharmaceutical wholesaler operations, to fully focus on the branded and specialty pharma segment. Scienture, LLC’s Story Scienture, LLC (previously known as Scienture, Inc.) was founded in June 2019 as a branded specialty pharmaceutical company with a mission to address critical gaps in patient care by challenging treatment paradigms, product safety and efficacy limitations, access and adherence hurdles, to deliver better patient solutions. It is committed to creating value by developing robust in-house platforms, acquiring or in-licensing differentiated products and nuanced commercialization, that address the needs of patients and caregivers. Central to Scienture, LLC’s vision is its well thought out and diverse product pipeline under development, which spans multiple therapeutic areas, indications, and market segments. Its agile commercialization model and capabilities in sales and marketing, ensures flexibility and broad reach in delivering impactful results. Executing and supporting this comprehensive vision are its founding and executive management teams and strategic partners, who have several years of industry experience and an impeccable track record of building and growing successful companies. Key Accomplishments to Date Through Scienture, LLC, we have demonstrated a strong track record of success in the achievement of several key and critical milestones associated with product development, regulatory filings and approvals, proprietary intellectual property filings, business development activities and structuring commercial operations and go to market infrastructure. Product Development No.ItemAccomplishments1.SCN-102 (ArbliTM) Completed all development activities and the filing and receiving final approval of the NDA from the FDAFinalized contract with strategic partner for the manufacturing and commercial supply of finished product.Filed three (3) Intellectual Property filings resulting in two (2) granted patents and one (1) patent application pending, which provide coverage till 2041 in the US market. The patents are eligible for listing in the FDA Orangebook. 2.SCN-104 Devised an innovative product strategy for an injectable pen formulation and device to treat migraine patientsSuccessfully completed all initial development activities and initial meeting with the FDA to finalize regulatory pathway for approval.Contracted with strategic partner based in US, Germany and Canada for all development and manufacturing activities, inclusive of pen device and cartridge filling.Continued product development, paving the way for targeting registration NDA batches for the product in 2025 and potential NDA filing in 2026.Filed Intellectual Property applications and work is ongoing to facilitate patent issuance. 3.SCN-106 Identified and initiated development activities on a value added biosimilar product in the CVS therapeutic area.Successfully contracted with a strategic partner with accomplished biologics development and manufacturing capabilities based in India for the development and manufacturing of the product.Completed successful FDA meetings for the determination of next steps of development and the full pathway to BLA approval.Continue to lead the execution of the product in 2025 and beyond to accomplish potential BLA filing in 2028. 4.SCN-107 Established an innovative product concept and development program for the non-opioid management of post-surgical pain, offering significant value to patients and caregivers.Structured a strategic collaboration with an EU-based partner for leveraging using novel, unique polymers and microsphere processing technologies.Completed successful FDA meetings for next steps of development and to formalize full development pathway for NDA filing and approval.Successfully filed Intellectual Property applications and work is ongoing to facilitate patent issuance. Business Development On March 4 of this year, Scienture, LLC executed a Definitive Agreement for the for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024. REZENOPY® is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of the active ingredient and form factor, with increased effectiveness against potent opioids. IQVIA data (MAT December 2024) indicates a total annual sales of $189 million, unit volume of $10.0 million (eaches) for Naloxone in the US market. Commercial Operations We have a robust and nimble commercial operations strategy and program to successfully launch Scienture, LLC’s commercial products, ArbliTM and REZENOPY®, in 2025 and other products in the future, as it continues to grow. Our experienced internal leadership and industry leading partners provide a strong platform across several key functional areas focused on driving market performance: Field Operations, Virtual Promotion, Digital Marketing and CRMBranding, Promotional Materials and Website ManagementPayor Contracting and Market AccessDistribution and Logistics Provider; GTN and O2C mgmt.Data Analytics and Market IntelligenceBroad Channel Access – Retail, Institutional and DTCGovernment Contracting and Access What’s Next Over the next 12 months, we will be focused on: Successful launches of Scienture, LLC’s two (2) commercial products to obtain meaningful market share and providing a platform for growth and profitability. IQVIA data (December 2024) indicates a combined total annual sales of $481 million for Losartan ($292 million) and Naloxone ($189 million) in the US market.Continue to execute seamlessly on all our product development initiatives and drive relentlessly through to regulatory filings and approvalContinue to leverage our deep industry networks to identify and close on potential revenue and margin opportunities through business development and licensing.Continue to empower and strategically enhance our workforce to deliver strong results Why Us and Why does it matter We are a holding company of a fully fitted specialty pharma company passionate about delivering innovative solutions across the healthcare landscape. Our unique model brings a confluence of talent, experience and a culture of success across product development, manufacturing, commercial operations and strategic partnerships. Even with the advent of ground-breaking technologies and treatment options, the pharmaceutical industry continues to face challenges in providing adequate care due to an aging population, rising healthcare expenditure, increasing prevalence of chronic diseases, stringent regulatory requirements and high development costs. Our value added approach to reinventing existing molecules through innovative technology provides elegant options to overcome these limitations. We seek to expand access and improve clinical outcomes through safe and efficacious products using targeted delivery mechanisms, which should enhance patient compliance and convenience and provide overall cost savings to the healthcare system. Scienture, LLC’s well thought out product pipeline continues to expand, starting with our near term and upcoming commercial launches. Scienture, LLC’s flexible and modular commercial model drives efficiency and synergies through all our operations while retaining its comprehensive go to market capabilities. Final Thoughts This year was about enhancing and building on the strong foundation that was laid for our company. The years ahead will involve focusing on the execution, growth and expansion of our differentiated capabilities to create value to patients, caregivers, healthcare system and our shareholders. Thank you for your continued support as we endeavor on this journey of bringing meaningful products and innovation to the specialty pharma landscape. About Scienture Holdings, Inc. SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, including Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture, LLC are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit and www.scienture.com. Forward-Looking Statements This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “seek,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law. For more information, please contact:IR@Scienture.com

March 18, 2025 -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc., with the brand name ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL. ArbliTM is meant for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes. ArbliTM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market. ArbliTM is a novel proprietary formulation of losartan, a proven therapy for treating hypertension, which provides a tailored approach to patients that require or prefer an oral liquid option of losartan. Appropriate dosing is now easier, safe and effective, while providing the assurance of quality as an FDA-approved product. ArbliTM provides a safe and convenient option to patients requiring a liquid formulation and addresses the intrinsic risks associated with potential inconsistencies in the process of crushing tablets to extemporaneously compound losartan prescriptions. ArbliTM has two issued patents from the USPTO, which are also expected to be listed in the FDA Orangebook. Losartan is classified as an angiotensin receptor blocker (ARB) for treating hypertension and is one of the highest prescribed molecules for this indication. Current products in the market containing losartan are available only as oral solids, which can be further compounded to a liquid formulation. ArbliTM is the first liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. IQVIA data (MAT December 2024) indicates a total annual sales of approximately $292 million and a prescription volume of 68 million (TRx) for losartan in the US market. “The approval of ArbliTM exemplifies our deep commitment to develop high value products that address unique and underserved patient needs. A significant number of patients can benefit from a safe and efficacious ready-to-use oral liquid formulation of losartan. We are excited with the approval of our first brand product which is part of our upcoming pipeline of novel specialty products,” remarked Shankar Hariharan, CEO of Scienture, LLC. “We are pleased to bring to market, ArbliTM, a transformative therapy option containing losartan, one of the most widely prescribed molecules in its class, to patients, caregivers and healthcare professionals (HCPs). We expect to commercially launch and make ArbliTM available to patients in the U.S. in Q3 2025,” said Narasimhan Mani, President of Scienture, LLC. “This announcement is extremely exciting and is a clear demonstration of the value Scienture, LLC brings to the combined company and its shareholders,” said Suren Ajjarapu, Chairman of the Board, Scienture Holdings, Inc. ArbliTM is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 18 months from the date of manufacture when stored at room temperature, based on the data submitted in the NDA. Once the 24-months stability data is submitted to the FDA, the shelf-life of the product is expected to be extended to 24-months at room temperature. Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg. SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit www.scienture.com. The content above comes from the network. if any infringement, please contact us to modify.